IN2014DE00822A - - Google Patents

Download PDF

Info

Publication number
IN2014DE00822A
IN2014DE00822A IN822DE2014A IN2014DE00822A IN 2014DE00822 A IN2014DE00822 A IN 2014DE00822A IN 822DE2014 A IN822DE2014 A IN 822DE2014A IN 2014DE00822 A IN2014DE00822 A IN 2014DE00822A
Authority
IN
India
Prior art keywords
subject
borapetoside
metabolite
prodrug
solvate
Prior art date
Application number
Inventor
Ming-Jai Su
Shoei-Sheng Lee
Original Assignee
Orient Europharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orient Europharma Co Ltd filed Critical Orient Europharma Co Ltd
Priority to IN822DE2014 priority Critical patent/IN2014DE00822A/en
Publication of IN2014DE00822A publication Critical patent/IN2014DE00822A/en

Links

Abstract

The present invention is directed to therapeutic methods and compositions for treating type 1 diabetes in a subject comprising administering an effective amount of borapetoside A or C, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, and insulin to said subject.
IN822DE2014 2014-03-20 2014-03-20 IN2014DE00822A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN822DE2014 IN2014DE00822A (en) 2014-03-20 2014-03-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN822DE2014 IN2014DE00822A (en) 2014-03-20 2014-03-20

Publications (1)

Publication Number Publication Date
IN2014DE00822A true IN2014DE00822A (en) 2015-09-25

Family

ID=54394335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN822DE2014 IN2014DE00822A (en) 2014-03-20 2014-03-20

Country Status (1)

Country Link
IN (1) IN2014DE00822A (en)

Similar Documents

Publication Publication Date Title
SA521421115B1 (en) Carbidopa and L-DOPA Prodrugs and Methods of Use
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
MX2020011104A (en) Pharmaceutical compositions of therapeutically active compounds.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2018003893A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough.
MX2016011865A (en) Pharmaceutical compositions of therapeutically active compounds.
PH12016502352A1 (en) Pharmaceutical composition
MX2016011105A (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders.
TW201613578A (en) Pharmaceutical combinations
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2017014301A (en) Compositions and methods for the treatment or prevention of pulmonary hypertension.
IN2014DE00822A (en)
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MX2018004532A (en) Combination of trazodone and gabapentin for the treatment of pain.
IN2014DE00818A (en)
MX2017013103A (en) Methods for the treatment of cardiovascular disorders.
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds